Processa Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Processa Pharmaceuticals, Inc. (PCSA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $257.28 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2024-03-29
- Processa Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $257.28.
- Processa Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $16.80, a 0.00% change from fiscal 2020.
- Processa Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2020 was $16.80, a 0.00% change from fiscal 2019.
- Processa Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2019 was $16.80.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2023-12-31 | $257.28 10-K · filed 2024-03-29 |
| 2021-12-31 | $16.80 10-K · filed 2023-03-30 |
| 2020-12-31 | $16.80 10-K · filed 2022-03-30 |
| 2019-12-31 | $16.80 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |